A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Epstein-Barr virus-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Lymphoproliferative disorders; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Atara Biotherapeutics
- 10 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 10 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.
- 03 Jan 2017 According to an Atara Biotherapeutics media release, the Company plans to submit in 2018 an application for Conditional Marketing Authorization Approval of ATA 129 in the treatment of patients with rituximab refractory EBV-PTLD following hematopoietic cell transplant (HCT). The Conditional MAA will be based on data from phase I and II studies and supported by available data from the pase III studies in rituximab refractory EBV-PTLD after HCT and solid organ transplantation (SOT).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History